Intraperitoneal Chemotherapy in India

Intraperitoneal chemotherapy (IP chemotherapy) delivers anticancer medicine directly into the peritoneal cavity — the space inside the abdomen that surrounds many abdominal organs. Instead of relying only on intravenous chemotherapy, this route places medicine close to cancer deposits on the peritoneal surfaces.

There is a named GAF Healthcare partner planning sheet for intraperitoneal chemotherapy: $5,000–$14,000, typically tied to cytoreduction or IP ports. Neighbouring United States comparison figures on the same sheet are $20,000–$55,000. That India band is a pathway planning range for oncology review, port or catheter access, selected IP administrations and associated hospital care. It is not the price of a single instillation and it is not a CRS-HIPEC quotation.

IP chemotherapy is not the same as HIPEC. Conventional IP treatment may be given through a catheter over one or more sessions. HIPEC surgery in India is heated chemotherapy delivered during cytoreductive surgery. Neighbouring cytoreductive surgery with HIPEC is $18,000–$40,000, typically 10–21 nights. Neighbouring cytoreductive surgery is $10,000–$24,000, typically 7–14 nights. Neighbouring PIPAC is $7,000–$16,000, typically 2–5 nights. Neighbouring ovarian cancer cytoreductive surgery is $8,000–$20,000, typically 6–12 nights. Neighbouring chemotherapy is $1,500–$8,000+, typically outpatient cycles over 3–6 months. Named chemotherapy lists sit on Chemotherapy in India. Neighbouring immunotherapy is $15,000–$45,000. Neighbouring targeted therapy is $8,000–$30,000. Neighbouring molecular targeted therapy is $10,000–$32,000. Neighbouring neoadjuvant chemotherapy and adjuvant chemotherapy sit on their own sheets. Neighbouring precision oncology is $2,000–$7,000.

Disease pathways sit on ovarian cancer treatment in India and colon cancer treatment in India. Selected pancreatic peritoneal discussion sits on pancreatic cancer treatment in India. There is no live GAF peritoneal-cancer-only, PIPAC-only, fallopian-tube-only, appendiceal-only or mesothelioma-only treatment page.

Important: Intraperitoneal chemotherapy is a specialised oncology procedure. The actual hospital quotation depends on cancer type, residual disease, catheter versus operative delivery, medicines, number of cycles, kidney function and whether cytoreductive surgery or HIPEC is also required. A quotation should be obtained only after records review.

What is intraperitoneal chemotherapy?

Intraperitoneal chemotherapy is a type of regional chemotherapy. The drug is introduced directly into the peritoneal cavity rather than being administered exclusively through a vein.

The peritoneum is a thin membrane lining the abdominal cavity and covering many abdominal organs. Some cancers can spread along this surface, producing multiple small tumour deposits or more extensive peritoneal disease.

Delivering chemotherapy directly into this compartment can produce a much higher drug exposure around peritoneal tumour deposits than conventional systemic treatment alone for certain drugs. Some of the medication is also absorbed into the bloodstream, so IP chemotherapy can have both regional and systemic effects.

Higher local drug exposure does not automatically mean better treatment for every patient. The advantages have to be balanced against toxicity, technical feasibility, kidney function, abdominal anatomy, previous surgery and the evidence for the particular cancer being treated.

Intraperitoneal versus intravenous chemotherapy

The main difference is where the chemotherapy is initially delivered.

Intravenous chemotherapy is administered into a vein and enters the bloodstream. It circulates throughout the body and can reach cancer cells in multiple locations. Neighbouring chemotherapy remains $1,500–$8,000+ when the parent systemic protocol is named separately.

Intraperitoneal chemotherapy is introduced directly into the abdominal cavity. This creates substantial exposure within the peritoneal compartment while some drug is subsequently absorbed systemically.

Feature	Intravenous chemotherapy	Intraperitoneal chemotherapy
Primary route	Vein	Peritoneal cavity
Main exposure	Systemic	Regional plus some systemic exposure
Requires abdominal catheter or port	No	Usually
Used alone or with other treatment	Yes	Often integrated into a broader treatment plan
Appropriate for every cancer	No	No
Monitoring requirements	Significant	Significant, with additional catheter and abdominal considerations
Common role	Broad systemic cancer treatment	Selected peritoneal or abdominal malignancies

The choice between IV, IP or combined treatment should be made by the oncology team based on the disease and available evidence rather than simply choosing the route that delivers the highest concentration.

Is intraperitoneal chemotherapy the same as HIPEC?

No.

This distinction is particularly important for patients searching for intraperitoneal chemotherapy in India, because the terms are sometimes used interchangeably online.

Conventional IP chemotherapy is administered directly into the abdominal cavity, commonly through an implanted catheter and port. It can be delivered as part of a planned series of treatments.

HIPEC stands for hyperthermic intraperitoneal chemotherapy. It is generally performed after surgeons remove visible peritoneal tumour during cytoreductive surgery. A heated chemotherapy solution is then circulated through the abdominal cavity. See HIPEC surgery in India. Neighbouring CRS with HIPEC is $18,000–$40,000, typically 10–21 nights.

Feature	IP chemotherapy	HIPEC
Full name	Intraperitoneal chemotherapy	Hyperthermic intraperitoneal chemotherapy
Temperature	Usually not intentionally heated	Heated
Major surgery required	Not necessarily	Yes
Typical setting	Catheter or port-based treatment	Operating room
Often combined with CRS	Not necessarily	Yes
Main objective	Regional chemotherapy exposure	Treat microscopic residual disease after cytoreduction
Patient selection	Highly individualised	Highly selective
Recovery	Depends on regimen and catheter placement	Major postoperative recovery
GAF Healthcare India planning	$5,000–$14,000	$18,000–$40,000

How does intraperitoneal chemotherapy work?

Cancer cells may remain on the surfaces of the peritoneum after surgery or may have spread throughout the abdominal cavity. When chemotherapy is placed directly into the peritoneal cavity, the drug comes into close contact with these surfaces.

This can create a regional concentration advantage for selected drugs. The drug then gradually crosses the peritoneal tissues and can enter the bloodstream. Consequently, IP chemotherapy should not be thought of as a treatment that remains entirely inside the abdomen.

The exact benefit depends on cancer type, drug, concentration, duration of exposure, tumour size and distribution, blood supply, previous surgery, peritoneal adhesions, kidney and other organ function, whether residual disease remains after surgery, and whether systemic chemotherapy is administered simultaneously or sequentially.

Which cancers may be treated?

IP chemotherapy has been investigated or used in selected patients with several malignancies involving the peritoneal cavity.

Ovarian cancer

Ovarian cancer is one of the best-known settings in which intraperitoneal chemotherapy has been studied. The approach has historically been evaluated particularly in patients with advanced epithelial ovarian cancer who have undergone optimal cytoreductive surgery.

Modern ovarian cancer treatment is individualised, and IP chemotherapy is not automatically appropriate for every patient. Treatment of advanced ovarian, fallopian-tube and primary peritoneal cancers can include systemic chemotherapy, intraperitoneal chemotherapy, targeted therapy and, in selected circumstances, HIPEC. See ovarian cancer treatment in India. Neighbouring ovarian cancer cytoreductive surgery is $8,000–$20,000.

Fallopian-tube cancer

Fallopian-tube cancers are treated within a similar disease framework to epithelial ovarian and primary peritoneal cancers. Depending on stage, pathology, surgical findings and previous therapy, a multidisciplinary team may consider systemic chemotherapy and, in selected situations, regional approaches such as IP chemotherapy. There is no live GAF fallopian-tube-only treatment page.

Primary peritoneal cancer

Primary peritoneal carcinoma can behave similarly to epithelial ovarian cancer and may involve extensive disease along the peritoneal surfaces. IP treatment may be considered in selected clinical situations, but treatment should be determined by a gynaecologic oncology and medical oncology team. There is no live GAF peritoneal-cancer-only treatment page.

Colorectal cancer with peritoneal metastases

Peritoneal metastases from colorectal cancer are a different clinical scenario. Selected patients may be evaluated for cytoreductive surgery and HIPEC at specialised peritoneal-surface oncology centres. This does not mean that conventional catheter-based IP chemotherapy is routinely appropriate for every patient with metastatic colorectal cancer. See colon cancer treatment in India and the stage 4 colon cancer treatment guide.

Appendiceal cancer and pseudomyxoma peritonei

Appendiceal cancers and pseudomyxoma peritonei frequently involve the peritoneal surfaces. In carefully selected patients, treatment can involve cytoreductive surgery with intraperitoneal chemotherapy, particularly HIPEC, depending on the histology and extent of disease. There is no live GAF appendiceal-only treatment page.

Peritoneal mesothelioma

Peritoneal mesothelioma is a rare cancer arising from the peritoneal lining. Patient selection for cytoreductive surgery, HIPEC and other intraperitoneal treatments is highly individualised. There is no live GAF mesothelioma-only treatment page.

Who may be considered?

Eligibility is not determined by the cancer name alone.

Doctors may consider histological diagnosis, stage, primary site, molecular and pathological characteristics, extent of peritoneal involvement, presence or absence of disease outside the abdomen, and previous response to chemotherapy.

For certain protocols, the amount of residual tumour after cytoreductive surgery is important. Historically, ovarian-cancer studies demonstrating benefit from IP treatment focused on patients who had undergone optimal cytoreduction.

Patient factors include kidney function, liver function, blood counts, nutritional status, performance status, cardiovascular health, respiratory function, previous abdominal operations, abdominal adhesions, ability to tolerate chemotherapy and ability to undergo surgery where applicable.

Evidence-based IP chemotherapy requires appropriate expertise and the ability to manage treatment-related toxicities.

When may it not be suitable?

IP chemotherapy may not be appropriate when the potential risks outweigh the expected benefits.

Potential concerns include poor kidney function, significant medical comorbidities, poor general condition, extensive abdominal adhesions, inability to safely place or maintain the catheter, a disease pattern that cannot be adequately exposed to the medication, extensive disease outside the peritoneal cavity, inability to tolerate chemotherapy, lack of evidence supporting IP treatment for the specific cancer, and previous severe toxicity from relevant chemotherapy drugs.

For patients undergoing CRS-HIPEC, additional considerations include the extent of peritoneal disease and whether complete or near-complete cytoreduction can reasonably be achieved.

How is intraperitoneal chemotherapy given?

Step 1: Cancer evaluation

The oncology team reviews biopsy and pathology reports, CT or MRI scans, previous chemotherapy, surgical history, blood tests, kidney function, tumour markers where relevant and overall physical condition.

Step 2: Catheter or port placement

A specialised catheter may be placed into the abdominal cavity. In some ovarian-cancer protocols, a catheter can be inserted during staging or debulking surgery, or later through a surgical or image-guided procedure. A port beneath the skin can then provide access for treatment.

Step 3: Chemotherapy administration

The chemotherapy solution is introduced through the catheter. The patient may be positioned or moved according to the treatment protocol so that the medication distributes adequately within the abdominal cavity. The exact drug, dose, volume and treatment schedule vary according to the cancer and institutional protocol.

Step 4: Monitoring

The medical team monitors pain, nausea and vomiting, fever, blood-pressure changes, kidney function, blood counts, catheter-related complications, infection and other chemotherapy toxicities.

What chemotherapy drugs are used?

There is no single IP chemotherapy drug used for every cancer. The drug depends on the malignancy, treatment objective and protocol.

For ovarian cancer, cisplatin and paclitaxel have been used in established IP chemotherapy regimens. Other intraperitoneal regimens may involve different agents depending on the cancer type and whether treatment is being delivered as conventional IP chemotherapy, HIPEC or another intraperitoneal technique.

The drug should never be selected based solely on an internet list. The oncologist chooses the regimen according to the patient's pathology, previous treatment and organ function.

Intraperitoneal chemotherapy for ovarian cancer

After surgery, microscopic cancer cells can remain within the abdominal cavity. IP chemotherapy attempts to expose these cells directly to anticancer medication.

Randomised trials established clinically meaningful benefits for certain optimally cytoreduced patients with advanced ovarian cancer, although treatment can also produce greater toxicity.

Treatment standards have evolved. Modern ovarian cancer care can include cytoreductive surgery, intravenous platinum-based chemotherapy, intraperitoneal chemotherapy in selected circumstances, targeted therapy, PARP inhibitors, bevacizumab in appropriate patients, HIPEC in selected settings and clinical trials.

A patient should not assume that IP chemotherapy is automatically preferable to modern IV-based treatment. Neighbouring targeted therapy is $8,000–$30,000. Named molecular-matched lists sit on Molecular Targeted Therapy in India. Neighbouring precision oncology is $2,000–$7,000.

Intraperitoneal chemotherapy after surgery

Surgery can remove visible tumour, but microscopic disease may remain. Depending on the cancer, the oncology team may recommend chemotherapy after surgery to reduce the risk of recurrence or control residual disease.

In selected ovarian-cancer patients, IP chemotherapy has been used after optimal cytoreduction. Eligibility is highly individualised and modern treatment pathways differ according to disease stage, molecular profile and treatment strategy. Neighbouring adjuvant chemotherapy is a different systemic sheet and is not an IP quotation. Named post-operative lists sit on Adjuvant Chemotherapy in India.

Intraperitoneal chemotherapy and cytoreductive surgery

For peritoneal-surface cancers, IP chemotherapy may form part of a larger treatment strategy.

Cytoreductive surgery attempts to remove visible peritoneal tumour. When HIPEC is used, chemotherapy is circulated inside the abdomen after cytoreduction.

The underlying principle is: remove visible disease → expose the abdominal cavity to regional chemotherapy → treat microscopic residual disease.

The success of this approach depends greatly on patient selection, tumour biology, disease burden and the ability to achieve adequate cytoreduction.

What is PCI?

The Peritoneal Cancer Index (PCI) is a scoring system used to describe the extent of peritoneal disease. The abdomen is divided into regions, and tumour deposits are assessed according to their size and distribution.

PCI helps the multidisciplinary team understand how extensive the peritoneal disease is, whether cytoreductive surgery may be technically feasible, the expected complexity of surgery, prognostic considerations and whether CRS/HIPEC may be appropriate.

PCI should not be interpreted as a universal yes/no cut-off for every cancer. Different tumour types behave differently, and the relationship between PCI, tumour biology and outcomes varies.

Benefits and limitations

Potential advantages include direct drug delivery, high local exposure for selected drugs, some systemic absorption, usefulness when cancer is predominantly located within the abdominal cavity, and the option to complement rather than replace systemic treatment.

IP chemotherapy is technically more demanding than routine IV chemotherapy. Potential limitations include catheter complications, abdominal pain, infection, nausea and vomiting, kidney toxicity with some drugs, blood-count abnormalities, treatment interruptions, adhesions affecting drug distribution, greater treatment burden and the need for specialised oncology expertise.

Side effects

Side effects depend on the drug and treatment protocol.

Possible gastrointestinal effects include nausea, vomiting, abdominal discomfort, loss of appetite, diarrhoea or constipation.

Chemotherapy can suppress bone marrow, potentially causing anaemia, low white-cell counts, low platelet counts and increased infection risk.

Some chemotherapy drugs, particularly platinum agents such as cisplatin, can affect kidney function. This is one reason renal function is carefully assessed before and during treatment.

Some drugs can cause peripheral neuropathy, resulting in tingling, numbness, burning sensations or sensitivity changes.

Patients with implanted ports or catheters can experience infection, blockage, leakage, malposition or abdominal discomfort.

Depending on the drug, patients may also experience fatigue, hair loss, changes in taste, appetite changes, electrolyte abnormalities or allergic reactions.

If severe or persistent abdominal pain, fever, catheter leakage, sudden swelling, collapse, anuria or rapidly worsening vomiting develops, seek a local emergency department immediately. Do not wait for a later clinic visit or use WhatsApp as emergency care.

IP chemotherapy versus HIPEC versus PIPAC

Patients researching peritoneal cancer treatment may encounter three different terms.

Treatment	Basic concept	Typical setting	GAF Healthcare India planning
IP chemotherapy	Chemotherapy placed directly into the peritoneal cavity	Catheter or port-based treatment	$5,000–$14,000
HIPEC	Heated chemotherapy circulated during or after cytoreductive surgery	Operating room	$18,000–$40,000
PIPAC	Pressurised aerosol chemotherapy delivered laparoscopically	Minimally invasive operating procedure	$7,000–$16,000

These treatments should not be presented as interchangeable. Their indications, evidence, treatment objectives and patient-selection criteria differ. There is no live GAF PIPAC treatment page; the named sheet is PIPAC.

PIPAC aerosolises the drug and delivers it into the abdominal cavity under pressure during a minimally invasive procedure. It has been investigated particularly for peritoneal metastases that are difficult to treat with conventional approaches. It remains a specialised treatment and should generally be considered within experienced peritoneal oncology programmes and, where appropriate, clinical research protocols.

How long does treatment take?

There is no single duration applicable to all IP chemotherapy. Time depends on the drug, dose, infusion protocol, catheter or port system, cancer type, whether it is part of a surgical procedure and the institutional protocol.

HIPEC is different: the heated perfusion itself is commonly delivered over a defined intraoperative period, while the complete CRS-HIPEC operation can take several hours because the surgical cytoreduction may be extensive. Neighbouring stay on the HIPEC sheet is 10–21 nights. Catheter IP stay on this sheet is tied to cytoreduction or IP ports.

Recovery

Recovery depends on whether the patient receives conventional catheter-based IP chemotherapy or undergoes CRS-HIPEC.

Recovery from each conventional administration may be relatively short, although chemotherapy side effects can continue for several days.

Recovery after CRS-HIPEC is substantially longer because the patient has undergone major abdominal surgery. Postoperative care may include pain management, fluid and electrolyte management, nutritional support, early mobilisation, respiratory exercises, infection prevention, blood-count monitoring, kidney-function monitoring and physiotherapy.

Urgent local emergency assessment is necessary if the patient develops severe abdominal pain, fever, catheter leakage, collapse, anuria or rapidly worsening vomiting.

Preparing for treatment in India

Patients travelling to India should ideally complete a detailed medical evaluation before booking treatment.

Prepare biopsy reports, histopathology slides or blocks where available, immunohistochemistry reports, CT/MRI/PET-CT reports and images, previous operative notes, previous chemotherapy and radiotherapy records, current medication lists, blood investigations, kidney and liver function reports, tumour-marker results where relevant, discharge summaries and genetic or molecular testing reports where available.

For international patients, digital copies should be organised chronologically so the treating team can review the treatment history efficiently.

How doctors assess a patient

A multidisciplinary team may include a medical oncologist, surgical oncologist, gynaecologic oncologist, radiologist, pathologist, anaesthetist, critical-care specialist, nutritionist, physiotherapist and specialised oncology nursing team.

This is particularly important for CRS-HIPEC because treatment involves major surgery, chemotherapy and complex perioperative management.

Depending on the disease, doctors may request contrast-enhanced CT of the abdomen and pelvis, CT chest, MRI in selected circumstances, PET-CT in selected cancers, complete blood count, kidney and liver function, electrolytes, coagulation tests, tumour markers where clinically relevant, histopathology, immunohistochemistry and molecular testing where appropriate.

For suspected peritoneal-surface malignancy, the team may need to determine whether the disease can be adequately resected.

Cost of intraperitoneal chemotherapy in India

There is no single standard price. GAF Healthcare partner planning for the named intraperitoneal chemotherapy pathway is $5,000–$14,000, typically tied to cytoreduction or IP ports. Neighbouring United States comparison figures are $20,000–$55,000.

The final hospital quotation can vary substantially depending on whether the patient receives conventional catheter-based IP chemotherapy or a larger procedure such as CRS-HIPEC.

Major cost factors include cancer type, chemotherapy drugs, number of treatment cycles, drug dosage, catheter or port placement, surgeon and specialist fees, hospital charges, ICU requirement, operating-room costs, CRS complexity, HIPEC drugs and perfusion system, laboratory and imaging tests, length of hospitalisation, management of complications, additional systemic chemotherapy and supportive medicines.

A hospital-specific quotation based on the patient's medical records is more meaningful than a generic internet price.

For international patients, the treatment estimate should ideally separate consultation, diagnostic investigations, surgery if required, chemotherapy, HIPEC if applicable, hospitalisation, ICU, medicines and follow-up.

CRS-HIPEC involves substantially more resources than a catheter-based session. It should not be compared directly with the price of a single IP instillation.

Intraperitoneal chemotherapy cost by Indian city

There is no reliable single national tariff. GAF Healthcare uses one national partner planning band of $5,000–$14,000 rather than inventing city-specific prices.

International patients comparing medical oncologists listing Intraperitoneal Chemotherapy commonly start with Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. Partner medical oncology hospitals in Delhi NCR, Mumbai and Bengaluru, and in Chennai and Hyderabad, are a typical first filter. City sheets include Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. Neighbouring HIPEC surgical lists sit on Delhi NCR and Mumbai. Pune, Kolkata, Ahmedabad, Chandigarh and Jaipur are not live GAF catalog cities on this site.

City	Catalogue doctors list	India planning band
Delhi NCR	Medical oncologists listing Intraperitoneal Chemotherapy	$5,000–$14,000
Mumbai	Medical oncologists listing Intraperitoneal Chemotherapy	$5,000–$14,000
Bengaluru	Medical oncologists listing Intraperitoneal Chemotherapy	$5,000–$14,000
Chennai	Medical oncologists listing Intraperitoneal Chemotherapy	$5,000–$14,000
Hyderabad	Medical oncologists listing Intraperitoneal Chemotherapy	$5,000–$14,000

How to choose a centre

Patients should look beyond a hospital's general cancer reputation.

Ask whether the centre treats peritoneal-surface malignancies, whether it performs CRS-HIPEC if that route is being considered, who will manage the patient, whether a multidisciplinary team reviews the case, what experience the centre has with the specific cancer, and what postoperative support is available, including ICU, nutrition, physiotherapy and interventional radiology.

Experience with colorectal peritoneal metastases is not necessarily equivalent to experience with ovarian cancer, pseudomyxoma peritonei or peritoneal mesothelioma.

Why consider India?

India has specialised oncology programmes covering surgical oncology, gynaecologic oncology, gastrointestinal oncology, peritoneal-surface malignancy, CRS-HIPEC, medical oncology, interventional radiology, critical care and cancer pathology.

For international patients, the advantage of seeking care at a specialised centre is not simply access to a chemotherapy drug. It is access to the complete multidisciplinary treatment pathway.

Questions to ask before travel

1. Is my cancer suitable for intraperitoneal chemotherapy?
2. Is conventional IP chemotherapy or HIPEC being proposed?
3. Why is this route recommended for my cancer?
4. Will I also need IV chemotherapy?
5. Do I require cytoreductive surgery?
6. What is my estimated PCI?
7. Is complete cytoreduction considered achievable?
8. Which chemotherapy drug will be used?
9. How many cycles or sessions are expected?
10. How long will I need to stay in India?
11. How long is hospitalisation expected to last?
12. What are the major risks?
13. What is included in the treatment estimate?
14. What happens if complications occur?
15. What follow-up will be required after returning home?

A useful consultation should also cover the goal of treatment, whether the intention is curative, disease-control or palliative, what evidence supports the route, whether IV chemotherapy alone could be appropriate, how kidney function will be protected and how response will be monitored.

Frequently asked questions

Is intraperitoneal chemotherapy available in India?

Yes. Specialised cancer centres in India provide regional intraperitoneal treatment, including selected IP chemotherapy and CRS-HIPEC programmes.

Is IP chemotherapy better than IV chemotherapy?

There is no universal answer. The benefit depends on the cancer, stage, residual disease, treatment protocol and patient characteristics. IP chemotherapy has demonstrated benefits in selected ovarian-cancer settings but also carries greater toxicity.

Is intraperitoneal chemotherapy painful?

Treatment can cause abdominal discomfort or pain, particularly in some ovarian-cancer IP regimens. Catheter placement and chemotherapy itself may also cause discomfort. Pain-management strategies are available and should be discussed with the oncology team.

Does IP chemotherapy cause hair loss?

It can, depending on the chemotherapy drugs used and whether IV chemotherapy is also administered. Hair loss is a systemic chemotherapy effect rather than something unique to the intraperitoneal route.

Does IP chemotherapy affect the kidneys?

Some drugs used in IP treatment, particularly platinum drugs, can affect kidney function. Kidney function is therefore an important consideration before and during treatment.

Can IP chemotherapy be given after surgery?

Yes. In selected treatment protocols, IP chemotherapy can be administered after cytoreductive surgery.

Can IP chemotherapy be combined with IV chemotherapy?

Yes. Certain protocols deliberately combine regional IP treatment with systemic IV chemotherapy.

Is HIPEC a type of intraperitoneal chemotherapy?

Yes, in the broad sense that chemotherapy is delivered into the peritoneal cavity. However, HIPEC is a distinct treatment technique involving heated chemotherapy, generally during cytoreductive surgery.

Is HIPEC suitable for all peritoneal cancer patients?

No. Patient selection is critical. Disease distribution, tumour biology, performance status, comorbidities and the possibility of adequate cytoreduction all influence eligibility.

How long does IP chemotherapy take?

The duration varies by protocol, drug and cancer type. Conventional IP treatment and HIPEC have very different treatment schedules.

Can international patients receive IP chemotherapy in India?

Yes, international patients can seek evaluation at Indian cancer centres. Treatment should be planned after review of pathology, imaging and previous treatment records.

What happens if the disease has spread outside the abdomen?

Systemic therapy may become particularly important because chemotherapy delivered into the peritoneal cavity does not replace treatment for disease at distant sites.

Can IP chemotherapy cure cancer?

Some patients may achieve long-term disease control or remission, but IP chemotherapy is not a guaranteed cure. The prognosis depends on the underlying cancer, disease extent, tumour biology and response to treatment.

When should you seek a second opinion?

A second opinion can be useful when CRS-HIPEC has been recommended, different oncologists have suggested different chemotherapy routes, surgery is being considered, the disease has recurred, the cancer is resistant to previous chemotherapy, the treatment plan involves a major abdominal operation, the diagnosis is rare, or you are unsure whether IP chemotherapy is supported by evidence for your specific cancer.

For rare peritoneal cancers, obtaining review by a specialist team with experience in peritoneal-surface malignancy can be particularly valuable.

Key takeaways

• GAF Healthcare partner planning for this pathway is $5,000–$14,000, typically tied to cytoreduction or IP ports.
• Neighbouring United States comparison figures are $20,000–$55,000.
• Neighbouring CRS-HIPEC planning is $18,000–$40,000. Neighbouring PIPAC planning is $7,000–$16,000.
• Conventional IP chemotherapy and HIPEC are not interchangeable.
• The route is used in selected ovarian, fallopian-tube, primary peritoneal and other peritoneal-surface malignancies.
• It is a treatment modality, not a guaranteed cure.
• International patients should obtain a regimen-specific hospital quotation after medical-record review.
• Always confirm whether a quotation is catheter IP, HIPEC or PIPAC before making travel or treatment decisions.

Medical disclaimer

This page is intended for educational and treatment-cost planning purposes and should not replace consultation with a qualified oncologist. Intraperitoneal chemotherapy, HIPEC and other regional cancer treatments have different indications and evidence depending on the cancer type.

Cost figures are indicative and may change according to hospital, city, cancer diagnosis, chemotherapy drug, dose, number of sessions, investigations, specialist fees, admission requirements and other clinical factors.

Treatment decisions should be made after review of the patient's pathology, imaging, medical history and overall condition by an appropriate multidisciplinary cancer team.

Last reviewed: October 2026

Sources and references

1. National Cancer Institute (NCI) — HIPEC definition and treatment information
2. National Cancer Institute (NCI) — Treatment of ovarian epithelial, fallopian-tube and primary peritoneal cancers
3. American Cancer Society — Chemotherapy for ovarian cancer
4. ASCO — Assessment and treatment of epithelial ovarian cancer
5. INDEPSO–ISPSM — Indian consensus on ERAS for CRS with or without HIPEC
6. Society of Onco-Anaesthesia and Perioperative Care — CRS-HIPEC consensus guidelines
7. INDEPSO–ISPSM — Consensus on peritoneal mesothelioma
8. GAF Healthcare cost sheet — Intraperitoneal Chemotherapy ($5,000–$14,000; tied to cytoreduction or IP ports)
9. GAF Healthcare cost sheet — Cytoreductive Surgery with HIPEC ($18,000–$40,000; 10–21 nights)
10. GAF Healthcare cost sheet — PIPAC ($7,000–$16,000; 2–5 nights)

Medical information should be interpreted in the context of current clinical guidelines and the individual patient's diagnosis. Published hospital and provider cost estimates are indicative and can change without notice.